

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



WINSHINE SCIENCE COMPANY LIMITED

瀛晟科學有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 209)

COMPLETION OF ISSUE OF CONVERTIBLE BONDS

References are made to (i) the announcement of the Company dated 14 October 2022 and the circular (the “**Circular**”) of the Company dated 3 November 2022 in relation to, among others, the issue of convertible bonds up to the aggregate principal amount of HK\$22,500,000 under specific mandate; and (ii) the announcement of the Company dated 8 May 2023 in relation to the acquisition of the target company (the “**Voluntary Announcement**”). Unless the context requires otherwise, capitalised terms used herein shall bear the same meanings as defined in the Circular.

The Company is pleased to announce that on 22 May 2023, the completion of the CB Subscription under CB Subscription Agreement A has taken place and the remaining Convertible Bonds in the principal amount of HK\$20,000,000 have been issued to Subscriber A. The acquisition as disclosed in the Voluntary Announcement is the subject investment as planned at the time of the CB Subscription. There has been no change of intended use of the remaining proceeds from the CB Subscription as disclosed in the Circular which will still be applied for the watermelon planting project of the Target Group in Japan for its capital expenditure and general working capital needs.

By Order of the Board
Winshine Science Company Limited
Zhao Deyong
Chairman

Hong Kong, 22 May 2023

As at the date of this announcement, the Board comprises three Executive Directors, namely Mr. Zhao Deyong (Chairman), Dr. Liao Wenjian (Chief Executive Officer) and Mr. Jiang Qinghui; one Non-executive Director, namely Mr. Lin Shaopeng; and three Independent Non-executive Directors, namely Mr. Kwok Kim Hung Eddie, Mr. Ng Wai Hung and Mr. Zhao Yong.

** For identification purpose only*